By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its monoclonal antibody (mAb) SHR-1819 in allergic rhinitis. This follows previous clinical trial approvals for the drug in conditions such as urticaria and atopic dermatitis in China.
SHR-1819: Mechanism and Applications
SHR-1819 is a human monoclonal antibody that binds to IL-4Rα, inhibiting the signaling pathways of both IL-4 and IL-13. This mechanism makes it a promising candidate for treating various allergic and inflammatory conditions. The expansion into allergic rhinitis highlights Hengrui’s commitment to broadening the therapeutic applications of its innovative biologic products.
Competitive Landscape
Globally, comparable products include Sanofi’s Dupixent (dupilumab) and Keymed Bio’s Kangyueda (stapokibart), both of which target similar pathways in allergic diseases. Hengrui’s SHR-1819 aims to offer a competitive alternative, potentially addressing unmet needs in the treatment of allergic rhinitis and other related conditions.-Fineline Info & Tech